Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

Eupraxia Pharmaceuticals announced it will present 4 abstracts at Digestive Disease Week (May 2-5, 2026) showcasing clinical data from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis. The presentations include an oral presentation on dose escalation leading to persistent histological improvements over 36 weeks, plus three poster presentations on endoscopic features, dysphagia improvements, and dose optimization. The company will also host a virtual investor event discussing esophageal strictures and EP-104GI's potential.

04/22/2026, 7:00 AM • GlobeNewswire

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals announced positive 36-week data from the highest dose cohort (Cohort 9) of its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis. The trial showed robust tissue health improvements with 90% reduction in EoEHSS Stage and 72% reduction in Peak Eosinophil Count, along with 66% clinical remission rate in symptoms. The drug demonstrated excellent safety with no serious adverse events reported across 31 patients and over 230 patient-months of follow-up. Phase 2b placebo-controlled results are expected in Q4 2026.

04/21/2026, 7:00 AM • GlobeNewswire

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.

04/13/2026, 1:00 PM • GlobeNewswire

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Eupraxia Pharmaceuticals announced the closing of a $63.2 million public offering and reported Q4 2025 financial results. The company achieved clinical milestones with its lead program EP-104GI in eosinophilic esophagitis, demonstrating positive tissue health data. Cash reserves increased to $80.5 million, with runway extending into the second half of 2028. However, net losses increased to $16.7 million in Q4 2025 compared to $7.5 million in Q4 2024, driven by higher R&D and administrative costs.

03/12/2026, 9:03 PM • GlobeNewswire

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

Eupraxia Pharmaceuticals successfully closed a $63.2 million public offering, including the full exercise of underwriter options. The company will use proceeds to advance EP-104GI for eosinophilic esophagitis through Phase 2 and Phase 3 clinical trials, expand pipeline candidates in additional gastrointestinal indications, and support commercial readiness preparations.

02/20/2026, 3:10 PM • Benzinga

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

Eupraxia Pharmaceuticals priced a US$55 million public offering of common shares at US$7.00 per share and pre-funded warrants at US$6.99999 per warrant. The company plans to use proceeds primarily for advancing EP-104GI for Eosinophilic Esophagitis through Phase 2 clinical trials and Phase 3 preparations, as well as expanding into additional gastrointestinal indications. The offering is expected to close on February 20, 2026.

02/19/2026, 2:18 AM • GlobeNewswire